Blepharospasm News and Research

RSS

Mapping the human dysfunctome with deep brain stimulation

A new study led by investigators from Mass General Brigham demonstrated the use of deep brain stimulation (DBS) to map a 'human dysfunctome' -; a collection of dysfunctional brain circuits associated with different disorders.

22 Feb 2024

Review examines visual disturbances among Parkinson’s disease patients

In a recent review published in Brain Sciences, researchers reviewed existing data on visual impairments among Parkinson’s disease (PD) patients.

9 Aug 2023

Researchers develop unique diagnostic tool to detect dystonia from MRI scans

Researchers at Mass Eye and Ear have developed a unique diagnostic tool that can detect dystonia from MRI scans, the first technology of its kind to provide an objective diagnosis of the disorder.

29 Sep 2020

Salk researchers develop new computer program to measure blepharosplasm severity

If two clinicians observe the same patient with blepharospasm -- uncontrollable muscle contractions around the eye -- they'll often come away with two different conclusions on the severity of the patient's symptoms.

24 Oct 2016

Studies show how speaking French could significantly reduce symptoms of Benign Essential Blepharospasm

A fascinating new study published in the latest edition of Movements Disorders (Vol.00 No.00, 2016) presents two patient case studies that demonstrate how speaking French as a second language can significantly reduce the symptoms of a life-limiting eye condition, Benign Essential Blepharospasm (BEB).

17 May 2016

Updated guidance on botulinum toxin formulations for four indications

The American Academy of Neurology has issued an update to its 2008 guidelines on the use of botulinum toxin for the treatment of spasticity, cervical dystonia, blepharospasm and migraine headache.

27 Apr 2016

AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research.

19 Apr 2016

Allergan Licenses Rights To Medytox Candidates, In Up-To-$362M Deal

...

26 Sep 2013

Botox Cosmetic receives FDA approval for treatment of crow’s feet lines

The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.

12 Sep 2013

Merz presents XEOMIN clinical data on dystonia at IDS 2011

New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.

22 Oct 2011

Merz launches 'Make Your Mark' campaign to raise awareness on cervical dystonia

Merz Pharmaceuticals, LLC, maker of XEOMIN, a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.

15 Apr 2011

Merz introduces new educational website for patients with focal dystonias

In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias, completing simple, everyday tasks can be a difficult and challenging process.

3 Feb 2011

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Botox receives FDA approval for treatment of chronic migraine

The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

18 Oct 2010

Xeomin botulinum toxin for cervical dystonia now available in the U.S.

Merz Pharmaceuticals today announced that Xeomin (incobotulinumtoxinA), a new botulinum toxin type A for the treatment of adults with cervical dystonia (CD)or blepharospasm, is now commercially available in the U.S. XEOMIN was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2010.

6 Oct 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.

19 Nov 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009